We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tengion CEO Nichtberger resigns

Tengion CEO Nichtberger resigns

July 1, 2011
CenterWatch Staff

Dr. Steven A. Nichtberger has resigned as president and CEO of Tengion, a regenerative medicine company focused on developing replacement organs and tissues grown from a person’s own cells, according to a report in the Philadelphia Business Journal.

Nichtberger is also stepping down from the company’s board of directors.

“I am pleased that as I leave my role at Tengion, the company is positioned to pursue the advancement of its organ regeneration platform and I wish Tengion success in bringing its product candidates to patients in need,” said Nichtberger in a statement released by the company.

Tengion of East Norriton, Pa., said David I. Scheer, the company’s board chairman, will assume a more active role in guiding the company while an external search is conducted for a new chief executive officer.

Nichtberger was at the helm at Tengion earlier this year when the company’s dwindling cash flow problem was resolved through a $31.4 million private stock sale.

Tengion reaffirmed its plan to submit next quarter to the FDA additional clinical data and modifications to the surgical approach for its experimental Neo-Urinary Conduit product.

The company also reiterated its plans to request a meeting with the FDA by the end of this year to discuss its plan for conducting clinical trials for its Neo-Kidney Augment product, which is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional kidney mass in patients with advanced chronic kidney disease.

United States Drug Sponsors

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing